by Karl Utermohlen | April 21, 2014 9:55 pm
Investor Will Ackman is behind a potential deal that could unite Allergan (AGN) and Valeant (VRX).
Ackman is pushing to merge the two medium-sized pharmaceuticals in a deal that would be worth around $42 billion. If a deal goes through, the combined company would have Valeant’s skin care portfolio and Allergan’s eye care products.
Allergan made a reported $6.3 billion in sales last year while Valeant reported $5.8 billion in revenue last year. The first company is run by CEO David Pyott who helped bring Botox into the mainstream.
News of a potential merger between Allergen and Valeant has seen both companies’ stock boom on Monday. AGN stock is up 6.03% while VRX stock is up 3.24% at closing.
More Drug Stock News
Source URL: https://investorplace.com/2014/04/agn-allergan-ackman-vrx-stock/
Short URL: http://invstplc.com/1tuH7nH
Copyright ©2017 InvestorPlace Media, LLC. All rights reserved. 700 Indian Springs Drive, Lancaster, PA 17601.